Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/652
Title: Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis
Authors: Gálvez, Rafael
Ribera, Victoria
González-Escalada, José Ramón
Souto, Alicia
Cánovas, María Luz
Castro, Andrés
Herrero, Begoña
Maqueda, María de los Ángeles
Castilforte, Matilde
Marco-Martínez, José Javier
Pérez, Concepción
Vicente-Fatela, Lorenza
Nieto, Consuelo
Orduña, Maria José
Padrol, Anna
Reig, Enrique
Carballido, Joaquín
Cózar, José Manuel
metadata.dc.contributor.authoraffiliation: [Gálvez,R] Pain and Palliative Care Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Ribera,V] Pain Unit, Hospital Vall d’Hebron, Barcelona, Spain. [González-Escalada,JR] Pain Unit, Hospital Ramón y Cajal, Madrid, Spain. [Cánovas,ML; Castro,A] Pain Unit, Hospital Cristal Piñor, Ourense, Spain. [Herrero,B; Maqueda,MA] Pain Unit, Hospital Virgen de la Macarena, Sevilla, Spain. [Castilforte,M] Pain Unit, Fundación Jiménez Díaz, Madrid, Spain. [Marco-Martínez,JJ] Pain Unit, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. [Pérez,C] Pain Unit, Hospital La Princesa, Madrid, Spain. [Vicente-Fatela,L] Pain Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. [Nieto,C] 10Pain Unit, Fundación Alcorcón, Madrid, Spain. [Orduña,MJ] Pain Unit, Hospital Xeral-Calde, Lugo, Spain. [Padrol] Pain Unit, Hospital Joan XXIII, Tarragona, Spain. [Reig, E] Pain Unit, Hospital Puerta del Hierro, Madrid, Spain. [Carballido,J] Urology Service, Hospital Puerta del Hierro, Madrid, Spain. [Cózar,JM] Urology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Keywords: Neoplasias de la Próstata;Metástasis de la Neoplasia;Dolor;Difosfonatos;Estudios Multicéntricos como Asunto;Masculino;Bone metastasis;Pain;Prostate cancer;Zoledronic acid
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation Agents
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
Medical Subject Headings::Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
Medical Subject Headings::Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Nervous System Physiological Processes::Sensation::Pain
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organophosphorus Compounds::Diphosphonates
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as Topic
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation Agents
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Bone Density Conservation Agents
Issue Date: Aug-2008
Publisher: Dove Medical Press
Citation: Galvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A et al. Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.Patient Prefer Adherence. 2008 Feb 2;2:215-24.
Abstract: Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis. Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire. Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatment Discussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.
URI: http://hdl.handle.net/10668/652
metadata.dc.relation.publisherversion: http://www.dovepress.com/articles.php?article_id=2083
metadata.dc.identifier.doi: 10.2147/PPA.S2314
ISSN: 1177-889X (Online)
Appears in Collections:01- Artículos - Hospital Virgen de las Nieves
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Galvez_Analgesic2008.pdfArtículo publicado929,21 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons